“Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s707. doi:10.25251/fpf9fe87.